5 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
European programme in Pharmacovigilance and Pharmacoepidemiology (EU2P)
Date du début: 1 sept. 2009, Date de fin: 30 juin 2016,
The Eu2P training network in Pharmacovigilance and Pharmacoepidemiology will meet the needs of industry,regulatory authorities and academia at the European level. It will give access to a harmonised training programme that gathers complementary specialized and eminent European partners. The Eu2P consortium consists of course providers with aproven record including the University of Bordeaux (Eu2P ...
Voir le projet
24
Participants partenaires
TERMINÉ
Microvesicle-inspired drug delivery systems (MINDS)
Date du début: 1 déc. 2010, Date de fin: 30 nov. 2015,
Current state-of-the-art drug carrier systems deliver new ‘biological drugs’ (like proteins and nucleic acids) poorly to the target site. This is something I daily experience in my research on delivery of small interfering RNA. The in vivo challenges are threefold:• Biological drugs are fragile molecules (subject to degradation and denaturation)• They need to gain access to the target site• They n ...
Voir le projet
2
Participants partenaires
TERMINÉ
Pharmacoepidemiolocal Research on Outcomes of Therapeutics by a European ConsorTium (PROTECT)
Date du début: 1 sept. 2009, Date de fin: 30 avr. 2015,
Recent pharmacovigilance (PV) issues have led to questions regarding the ability of the current PV system to meet the global needs. Controversies around the assessment of spontaneous reports and conflicting results from pharmacoepidemiology studies may lead to delay in, or inappropriate, regulatory decisions. The PROTECT consortium, consisting of 20 core partners lead by the European Medicines Age ...
Voir le projet
36
Participants partenaires
TERMINÉ
Access to Opioid Medication in Europe (ATOME)
Date du début: 1 déc. 2009, Date de fin: 30 nov. 2014,
"Medicines derived from opium are very valuable in medicine practice & therefore regarded as essential medicines. However, they are generally not readily available for patients who are in need of them for medical reasons. It is estimated that over 80% of the world's population is inadequately treated, because opioid (pain relieving) medicines have been categorized as ""controlled substances"", du ...
Voir le projet
11
Participants partenaires
TERMINÉ
A pharmacogenomic approach to coumarin anticoagulant therapy (EU-PACT)
Date du début: 1 oct. 2008, Date de fin: 31 mars 2013,
"The effectiveness of treatment with oral anticoagulants in the prevention of thrombotic disorders is well established, but these drugs are potentially dangerous because of their narrow therapeutic index. In Europe three coumarins are used: warfarin, acenocoumarol, and phenprocoumon. Genetic factors that have been recently demonstrated to change the pharmacokinetics and pharmacodynamics of coumari ...
Voir le projet